Skip to Content

Alzamend Neuro Inc Ordinary Shares - Stock Quote ALZN

Rating as of

Morningstar's Alzamend Neuro Inc Ordinary Shares Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics - ALZN

Alzamend Neuro Inc Ordinary Shares's Company Profile

Business Description

Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Contact
3500 Lenox Road NE, Suite 1500
Atlanta, GA, 30326
T +1 844 722-6333
Industry Biotechnology
Most Recent Earnings Jan 31, 2022
Fiscal Year End Apr 30, 2022
Stock Type Distressed
Employees 7